Radcliffe Capital Management’s Intelligent Medicine Acquisition Corp. Class A Common Stock IQMD Stock Holding History

Radcliffe Capital Management’s Portfolio IQMD Stock Details IQMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-300,890	Closed	-$3.09M	–	763
2022 Q4	$3.09M	Hold	300,890	–	–	0.1%	323
2022 Q3	$3.03M	Buy	300,890 +890	+0.3%	+$8.94K	0.07%	455
2022 Q2	$3.01M	Hold	300,000	–	–	0.07%	479
2022 Q1	$3M	Hold	300,000	–	–	0.07%	455
2021 Q4	$2.97M	Buy	+300,000	New	+$2.96M	0.08%	391

Other funds holding IQMD

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

Radcliffe Capital Management's IQMD Position: Q1 2023 in Review

Radcliffe Capital Management sold out of Intelligent Medicine Acquisition Corp. Class A Common Stock (IQMD) in Q1 2023, closing a stake of 300,890 shares — an estimated $3.09M sold.

Radcliffe Capital Management first reported a position in IQMD in Q4 2021 and held it in 5 quarters. The position peaked at $3.09M in Q4 2022. 8 funds tracked by Wall St. Rank hold IQMD as of Q1 2023.

Radcliffe Capital Management reported no remaining Intelligent Medicine Acquisition Corp. Class A Common Stock position as of Q1 2023 after selling out during the quarter.
Radcliffe Capital Management sold 300,890 Intelligent Medicine Acquisition Corp. Class A Common Stock shares in Q1 2023, an estimated $3.09M.
Radcliffe Capital Management first reported a position in Intelligent Medicine Acquisition Corp. Class A Common Stock in Q4 2021 and held it in 5 quarters.
Radcliffe Capital Management's Intelligent Medicine Acquisition Corp. Class A Common Stock position peaked at $3.09M in Q4 2022.
8 funds tracked by Wall St. Rank held Intelligent Medicine Acquisition Corp. Class A Common Stock as of Q1 2023.

Based on Radcliffe Capital Management's 13F filing for Q1 2023, filed 15 May 2023.